Sentences with phrase «median survival at»

Not exact matches

A follow - up of the 48 patients who were evaluable at a median time of 24 months indicated no statistical differences between the two groups in terms of overall or progression - free survival.

At a median follow - up of 2.74 years, the median recurrence - free survival was 26.1 months (95 % confidence interval (CI) 19.3 — 39.3) in the Ipilimumab group and 17.1 months (95 % CI 13.4 — 21.6) in the placebo group (hazard ratio 0.75; 95 % CI 0.64 — 0.90; p = 0.0013).

With standard treatments of surgery, chemotherapy and radiation, the median survival time is only 14.6 months, and improvement will only come with the ability to kill tumor cells resistant to standard treatments, according to Alfredo Quiñones - Hinojosa, M.D., a professor of neurosurgery at the Johns Hopkins University School of Medicine and a member of the research team.

Now, at 5.3 years median follow up, the impact on overall survival is reported and represents a 28 % reduction of the relative risk of death (hazard ratio 0.72, p = 0.001).

However, median progression - free survival is statistically significant, with the control group at about 8.6 months and the treatment group at 24.5 months — a 16 - month advantage for the ICT - 107 group.

Investigators then looked at what happened to these 140 five - year survivors over a median follow - up of 41 months (from the five - year survival point).

The team found that patients with more varied types of bacteria in their digestive tract had longer median progression - free survival, defined at the time point where half of studied patients have their disease progress.

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

The median survival age was 49.7 years in 2012, up from 31.9 years in 1990, Dr. Anne Stephenson, a respirologist and research at St. Michael's Hospital wrote in the European Respiratory Journal.

At five years, 34 of the 102 patients had achieved a complete response (disappearance of their cancer for a period of time), with an estimated 64 percent of patients surviving with or without disease (median five - year overall survival was 40.5 months) and an estimated 52 percent surviving without disease progression.

At five years, the rates for disease - free and overall survival were 26 percent and 40 percent, respectively, with a median overall survival of four years.

The progression - free survival at a median of 14 months of follow - up was 21.1 months but the progression - free survival for the responders, currently 19 patients, has not yet been reached.

Similarly, the median progression - free survival in both groups was the same, at 25.5 months, for an HR of 1.106 (95 % CI, 0.915 — 1.338).

When these mice were housed in chambers that contained normal air containing 21 percent oxygen, the equivalent of what a person would breathe at sea level, they developed brain lesions and had a median survival length of 58 days.

Quality of life was significantly higher in participants randomized to the intervention group, who demonstrated a statistically and clinically meaningful increase in QOL at 12 weeks (P <.05 using the nonparametric Wilcoxon test).31, 32 Median survival was almost 5 months longer in the intervention group.

Median overall survival, commonly referred to as median OS, is the time point at which 50 % of patients in a trial are expected to have surMedian overall survival, commonly referred to as median OS, is the time point at which 50 % of patients in a trial are expected to have surmedian OS, is the time point at which 50 % of patients in a trial are expected to have survived.

At a median follow - up of 65 months, both variables independently, negatively predicted disease progression, progression - free survival (PFS) and overall survival (OS).

In 25 soft tissue sarcoma (STS) patients with recurrent disease treated with CMB305, median overall survival (mOS) had still not yet been reached, with an overall survival rate at 12 and 18 months of 83 % and 76 %, respectively.

Even at the lower, suboptimal 8 - μg / kg dose level, IMGN632 increased the lifespan of the animals by 263 % compared with vehicle treatment (median survival, 102 vs 28 days, respectively).

Tumors of less than 1» diameter at the time of surgery have a median postoperative survival of 3 years.

The median survival in dogs treated with early chemotherapy alone (cisplatin or carboplatin) at Purdue University was 130 days.

In the 50 % of cats that showed at least some response to therapy, median survival time increased to 150 to 180 days as opposed to 75 to 86 days in the 50 % that did not respond.

Cats with advanced lung involvement at the time the tumor is diagnosed have a median survival time of only one month.

But in case of oral metastasis, the median survival time has been estimated at 16 - 24 months.

In the 50 % of cats that showed at least some response to therapy, median survival time increased to 150 - 180 days as opposed to 75 - 86 days in the 50 % that did not respond.